Teva Expects a Fall in Its Expenses and Cost Base in Fiscal 2018

Recently, Teva Pharmaceutical (TEVA) has witnessed trouble in its business due to a number of company-specific and macroeconomic factors. The Copaxone sales decline due to generic competition, the pricing pressures in the market, and the impairments recently recorded by Teva are among the major factors triggering the company’s restructuring to recuperate the decline in its sales and earnings. For more information, read The Key Challenges Teva Pharmaceutical Is Facing.